Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis

This is a multi-center, open-label study to assess the degree of systemic exposure and safety
of MM36 1% ointment following 4 weeks of twice daily dosing under maximal-use conditions in
pediatric subjects with atopic dermatitis.

Inclusion Criteria:

- Subjects 2 to <18 years of age

- Diagnosis of atopic dermatitis (AD)

- AD affecting ≥ 35% body surface area (BSA) if 2 to < 12 years of age or ≥ 25% if
subject is ≥ 12 years of age (excluding scalp and venous access areas)

Exclusion Criteria:

- Active or acute viral skin infection

- History of recurrent bacterial infection

- Malignancy

- Clinically significant history or physical findings that may pose a health risk to
subject or may have an impact on study assessments